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Abstract
Background: Treatments for coronary heart disease (CHD) have evolved rapidly over the last 15
years with considerable change in the number and effectiveness of both medical and surgical
treatments. This period has seen the rapid development and uptake of statin drugs and coronary
artery revascularization procedures (CARPs) that include Coronary Artery Bypass Graft
procedures (CABGs) and Percutaneous Coronary Interventions (PCIs). It is difficult in an era of
such rapid change to accurately forecast requirements for treatment services such as CARPs. In a
previous paper we have described and outlined the use of a Markov Monte Carlo simulation model
for analyzing and predicting the requirements for CARPs for the population of Western Australia
(Mannan et al, 2007). In this paper, we expand on the use of this model for forecasting CARPs in
Western Australia with a focus on the lack of adequate performance of the (standard) model for
forecasting CARPs in a period during the mid 1990s when there were considerable changes to
CARP technology and implementation policy and an exploration and demonstration of how the
standard model may be adapted to achieve better performance.
Methods: Selected key CARP event model probabilities are modified based on information
relating to changes in the effectiveness of CARPs from clinical trial evidence and an awareness of
trends in policy and practice of CARPs. These modified model probabilities and the ones obtained
by standard methods are used as inputs in our Markov simulation model.
Results: The projected numbers of CARPs in the population of Western Australia over 1995–99
only improve marginally when modifications to model probabilities are made to incorporate an
increase in effectiveness of PCI procedures. However, the projected numbers improve substantially
when, in addition, further modifications are incorporated that relate to the increased probability of
a PCI procedure and the reduced probability of a CABG procedure stemming from changed CARP
preference following the introduction of PCI operations involving stents.
Conclusion: There is often knowledge and sometimes quantitative evidence of the expected
impacts of changes in surgical practice and procedure effectiveness and these may be used to
improve forecasts of future requirements for CARPs in a population.
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Coronary heart disease (CHD) still remains the largest
single cause of death and a major cause of morbidity in
most developed countries [1]. Although rates of myocar-
dial infarction have fallen in most developed countries,
hospital admission rates for CHD have continued to rise
[2,3]. The treatment of CHD has meanwhile evolved, first
with the widespread uptake of effective short and long-
term medical treatment [4] and then with greater use of
coronary artery revascularisation procedures (CARPs)
[3,4] which started with coronary artery bypass grafting
(CABG) during the 1970s and evolved with percutaneous
coronary interventions (PCI) with the introduction and
rapid use of percutaneous transluminal coronary angi-
oplasty in the early 1980s, coronary artery stents in 1995
and more recently drug eluting stents [5]. The use of stents
has contributed to a decline in the risk of a repeat CARP
following PCI [5] while drug-eluting stents may lead to
further reductions in these risks [6,7]. Based on several
randomized controlled trials, CARPs are more effective
than medical treatment in reducing mortality and mor-
bidity from CHD [8,9].
There is great variation in rates of CARPs within and
between populations with comparable rates of CHD
[10,11]. Because of this uncertainty it is important to
develop probabilistic methods that model the require-
ments for CARPs at the population level by capturing
movement of individuals from one CHD/CARP state to
another based on the epidemiology and natural history of
CHD. This can be modelled by using Markov Monte Carlo
simulation.
This study is facilitated by the availability of a unique
Western Australian health information system which
allows identification and linkage of hospital admission
and deaths records pertaining to single individuals,
thereby providing a complete event history for CHD
patients [12]. In a previous paper we have described and
outlined the use of a Markov Monte Carlo simulation
model for predicting CHD incidence and requirements
for CARPs for the Western Australian population [13]. In
this paper, we expand on the use of this model for fore-
casting CARPs in Western Australia with a focus on how
the standard model may be adapted to achieve better fore-
casting performance if anticipated changes are incorpo-
rated. The 1995 Western Australian population cohort is
used to illustrate this approach with comparison of the
predicted and actual numbers of CARPs performed over
the period 1995 to 1999.
Methods
Statewide datasets comprising (linked) cardiovascular
hospital admissions for all persons who had a cardiovas-
cular-related admission for the period 1980 to 2001
together with all deaths and population census informa-
tion were used to establish CHD/CARP event history for
population cohorts and estimate (population) probabili-
ties of certain CHD and CARP events and deaths [13].
Under the Markov Monte Carlo simulation approach, for
the cohort comprising the population of Western Aus-
tralia aged 35–79 years at the beginning of 1995, model
simulations are conducted to predict the number of
CARPs (and other CHD events) that occur within the
cohort over the next 5 years. Under our Markov model the
cohort is split into initial history state groups (using their
known CHD/CARP history from the linked health infor-
mation system data back to 1980). The history states are
(1) a history of having a PCI some time in the past; (2) a
history of having a CABG some time in the past; (3) a his-
tory of having a CHD admission but no CABG or PCI
some time in the past; and (4) no history of CHD admis-
sion, CABG or PCI in the past. In the context of forecast-
ing, population transition probabilities that have been
estimated for past years (eg 1992 to 1994) are extrapo-
lated into future years for which forecasts are required (eg
1995 to 1999). These extrapolated probabilities are used
within the model to simulate events among cohort mem-
bers into the future (and taking into account the ageing of
the cohort). At the end of the first cycle people could have
moved to a different disease history state or moved into
one of two possible death (absorbing) states, namely (5)
death from CHD or (6) death from causes other than
CHD. Within a cycle, our model allows for a CHD admis-
sion without a CARP, up to two admissions with CABG or
PCI in addition to possible death (Figure 1). A more
detailed description of the model and the estimation of
population transition probabilities have been provided
elsewhere [13].
For extrapolating transition probabilities two standard
methods were used. These are (for each age, sex and his-
tory group) using the mean of the probabilities for the last
three years (the mean method) and using linear extrapo-
lation of transition probabilities based on the (weighted)
annual changes over the last three years with twice as
much weight assigned to the most recent annual change
(the linear method). The mean extrapolation method is
expected to perform well in situations when the (abso-
lute) level of the probabilities remains fairly constant into
the future and the linear extrapolation method is expected
to perform well in situations when the probabilities are
changing and are expected to continue to change at
approximately the same rate. Modified extrapolation
methods are obtained by modifying selected key proba-
bilities of CARP events and adopting the standard extrap-
olation probabilities for the rest of the model
probabilities.Page 2 of 11
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100 replicate simulations of the entire cohort [13]. The
accuracy of the total forecast number of CABGs and PCIs
is evaluated using the percent over- or under- compared to
the total actual number. The accuracy of forecasts across
age and sex groups is evaluated by calculating a goodness-
of-fit (GOF) observed-predicted chi-squared statistic. The
smaller the GOF statistic the better are the model fore-
casts. We used SAS version 9.0 [14] for calculating the sim-
ulation inputs and TreeAge Data Pro 2005 for Markov
simulation modelling [15].
No ethical approval was required for the project as the
data for this project were already provided to the research-
ers by the Data Linkage Unit of the WA Department of
Health.
Results
Table 1 shows the number and history distribution of the
WA 1995 population cohort. Overall 93.1% of men and
96.1% of women were in the 'no history of CHD' state but
this varied from 99.2% in 35–39 year old men to 76.2%
Schematic diagram for the recognised events during a cycle (year)Figure 1
Schematic diagram for the recognised events during a cycle (year).
History
No CHD adm CABG CHD 
 adm 
CABG PCI
CHD death Non-CHD death
 PCI 
Table 1: Age and sex distribution of the population of Western Australia for 1995
Sex Age group Hist no CHD Hist CHD Hist CABG Hist PCI Total Population
Male 35–39 70144 461 28 52 70685
Male 40–44 66197 818 100 142 67257
Male 45–49 61080 1290 294 314 62978
Male 50–54 44866 1689 506 445 47506
Male 55–59 34500 2048 779 563 37890
Male 60–64 27557 2522 1092 585 31756
Male 65–69 23852 2930 1309 576 28667
Male 70–74 17646 3097 1184 398 22325
Male 75–79 10297 2345 667 206 13515
Female 35–39 70024 301 6 4 70335
Female 40–44 66195 472 16 19 66702
Female 45–49 58333 632 29 46 59040
Female 50–54 42960 937 60 84 44041
Female 55–59 34614 1265 130 119 36128
Female 60–64 29418 1592 204 169 31383
Female 65–69 26848 2073 388 261 29570
Female 70–74 22407 2610 431 250 25698
Female 75–79 15694 2380 326 156 18556Page 3 of 11
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women to 84.6% in 75–79 year old women.
Tables 2 and 3 show the actual and forecast number of
CABGs and PCIs respectively for the standard models. The
results show that the mean method overestimates the
total actual number of CABGs by 20.5 percent and the lin-
ear method by 15.6 percent. The GOF values are reasona-
bly close for the two methods. The forecast numbers of
PCIs from the mean method under-estimates the actual
number of PCIs by 15.3 percent and the linear method
over-estimates by 17.7 percent. The GOF value is consid-
erably larger for the mean method.
The poor performance of these standard methods for fore-
casting the requirements of CARPs over 1995–99 may be
due to the fact that the effectiveness of PCIs increased after
1994 when stents were first introduced in WA and as a
result the probability of requiring another CARP within
the same year was reduced. Within the model these are
represented by risk of a CABG or another PCI in the same
year following a PCI procedure. For both males and
females, the trends in these probabilities for the largest
history group 'no history of CHD' are shown in Figures 2a,
2b, 3a and 3b. It is clear that the trend over the period
1992 to 1994 did not continue into 1995–1999 and
hence the standard extrapolation methods would not be
accurate for these probabilities.
Another explanation for the poor performance of the
standard methods was that there was an increasing trend
in PCI rates during the early 1990s as the number of facil-
ities performing PCIs increased and this continued until
about 1995 [6]. This, together with the increasing effec-
tiveness of PCIs meant that many more PCIs but fewer
CABGs were being performed. Within the model these are
captured by risk of a CABG and risk of a PCI. For both
sexes, the trends in these risks for the 'no CHD history'
group are shown in Figures 4a, 4b, 5a and 5b. It is clear
that the risk of a CABG and that of a PCI gradually
declined and increased respectively after 1994 for most
age groups 50–54 and above (the trends for younger age
Table 2: Comparison between actual numbers of CABGs and forecast numbers (1995–1999) based on the standard Mean and Linear 
extrapolation methods as well as selected modifications of these methods
Sex Age Group Actual Forecast 
under mean 
method
Forecast 
under 
modified 
mean method 
(Model 1)
Forecast 
under further 
modified 
mean method 
(Model 2)
Forecast 
under final 
modified 
mean method 
(Model 5)
Forecast 
under linear 
method
Forecast 
under 
modified 
linear 
method 
(Model 3)
Forecast 
under further 
modified 
linear method 
(Model 4)
Male 35–39 90 113 115 110 98 127 124 122
Male 40–44 206 271 278 265 239 271 266 262
Male 45–49 394 535 533 528 470 512 512 495
Male 50–54 601 733 730 719 637 697 696 678
Male 55–59 759 892 892 883 778 862 862 844
Male 60–64 829 1035 1028 1025 896 1009 1013 1007
Male 65–69 950 1075 1066 1065 930 1088 1078 1080
Male 70–74 678 771 773 769 667 810 808 810
Male 75–79 245 309 306 307 264 361 359 360
Male All 4752 5734 5721 5671 4979 5737 5718 5658
Female 35–39 22 16 18 15 15 14 15 15
Female 40–44 40 38 41 38 36 37 40 38
Female 45–49 49 82 85 72 76 70 70 69
Female 50–54 108 137 143 125 128 126 127 123
Female 55–59 152 216 224 213 200 200 199 197
Female 60–64 262 305 324 302 281 242 243 239
Female 65–69 319 392 417 387 362 283 284 276
Female 70–74 302 341 363 336 313 264 267 263
Female 75–79 151 161 169 161 145 145 144 142
Female All 1405 1688 1784 1649 1556 1381 1389 1362
Total 6157 7422 7505 7320 6535 7118 7107 6744
% change 
from actual
20.5 21.9 18.9 6.1 15.6 15.4 9.5
GOF 246.52 272.87 212.55 61.96 224.65 215.30 200.18Page 4 of 11
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sexes.
In order to incorporate modifications to the standard
extrapolation methods relating to the increased effective-
ness of PCI procedures (ie the decreased risk of requiring
a second CARP within the same year) we have examined
the clinical trial evidence for the improved effectiveness of
PCIs with stents. The results of a meta-analysis of 29 RCTs
by Brophy et al. [16] indicate that risk of a repeat PCI
would have declined by 41 percent in Western Australia
from 1995 due to the introduction of stents. The observed
risks for the Western Australian population showed that
the risk of a CABG after a PCI also declined by 41 percent
and thus we also reduce this risk accordingly.
To quantify the changed trends for PCI and CABG rates we
use evidence from a population based observational study
in Western Australia which showed that for males risk of
a PCI increased by about 25 percent and risk of a CABG
declined by about 15 percent when stents were introduced
in WA in 1995 [5]. For females, there were similar shifts
but the magnitude was about half that in males.
To accommodate these changed trends we have modified
the standard extrapolated probabilities for these events by
the amounts indicated by the evidence. Forecasts based on
the following modified models have been obtained and
the results are shown in Tables 2 and 3.
Model 1: the annual risk of a repeat PCI declines by 41
percent while the other risks are mean extrapolated,
Model 2: the annual risk of a repeat PCI and risk of a
CABG given PCI decline by 41 percent while the other
risks are mean extrapolated,
Model 3: the annual risk of a repeat PCI declines by 41
percent while the other risks are linearly extrapolated,
Table 3: Comparison between actual numbers of PCIs and forecast numbers (1995–1999) based on the standard Mean and Linear 
extrapolation methods as well as selected modifications of these
Sex Age Group Actual PCI Forecast 
under mean 
method
Forecast 
under 
modified 
mean 
method 
(Model 1)
Forecast 
under 
further 
modified 
mean 
method 
(Model 2)
Forecast 
under final 
modified 
mean 
method 
(Model 5)
Forecast 
under linear 
method
Forecast 
under 
modified 
linear 
method 
(Model 3)
Forecast 
under 
further 
modified 
linear 
method 
(Model 4)
Male 35–39 233 204 210 190 236 251 243 241
Male 40–44 412 423 424 401 492 554 527 526
Male 45–49 730 697 696 659 817 934 889 893
Male 50–54 788 800 807 754 917 1032 1008 1014
Male 55–59 909 819 824 779 950 1084 1013 1014
Male 60–64 888 762 767 717 880 1069 994 994
Male 65–69 878 662 665 632 769 1064 988 991
Male 70–74 716 414 417 393 477 745 694 698
Male 75–79 260 153 153 146 177 261 259 262
Male All 5814 4934 4963 4671 5715 6994 6615 6633
Female 35–39 24 19 21 20 23 26 26 25
Female 40–44 81 61 63 64 69 58 56 56
Female 45–49 119 134 136 138 148 135 129 128
Female 50–54 189 178 185 213 201 215 199 199
Female 55–59 250 221 230 222 249 285 262 260
Female 60–64 338 279 289 281 315 341 324 319
Female 65–69 381 326 339 329 364 436 411 414
Female 70–74 348 274 284 258 293 397 377 375
Female 75–79 197 129 136 122 134 219 205 205
Female All 1927 1621 1683 1647 1796 2112 1989 1981
Total 7741 6555 6646 6318 7511 9106 8604 8614
% change 
from actual
-15.3 -14.1 -18.4 -3.0 17.6 11.1 11.3
GOF 494.11 455.09 643.38 265.37 265.03 155.37 159.38Page 5 of 11
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CABG given PCI decline by 41 percent while the other
risks are linearly extrapolated, and
Model 5: the annual risk of a repeat PCI and risk of a
CABG given PCI decline by 41 percent and risk of a PCI
increases by 25 percent for males or 12.5 percent for
females with a corresponding decline in risk of a CABG by
a. Plot for risk of CABG within same year following a PCI, for people with no history of CHD by calendar year, for males with different age gr upsFigure 2
a. Plot for risk of CABG within same year following a PCI, for people with no history of CHD by calendar year, for males with 
different age groups. b. Plot for risk of CABG within same year following a PCI, for people with no history of CHD by calendar 
year, for females with different age groups
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other risks are mean extrapolated.
The results show that the forecast numbers of PCIs under
Model 1 become closer to the respective actual numbers
compared to standard mean extrapolation although the
discrepancies are still generally quite large. Also, this mod-
ification does not improve the forecasts for CABGs. The
forecasts for numbers of CABGs and PCIs under Models 2,
3 and 4 improve only marginally. There is over-estimation
in the actual number of CABGs by 21.9, 18.9, 15.4 and 9.5
percents respectively under Models 1, 2, 3 and 4. There is
a. Plot for risk of a repeat PCI within same year, for people with no history of CHD by calendar years, for males with different ge groupsFigu e 3
a. Plot for risk of a repeat PCI within same year, for people with no history of CHD by calendar years, for males with different 
age groups. b. Plot for risk of a repeat PCI within same year, for people with no history of CHD by calendar years, for females 
with different age groups
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and 18.4 percents respectively under Models 1 and 2, and
over-estimation by 11.1 and 11.3 percents under Models
3 and 4.
As the forecasts under Model 3 which use linear extrapo-
lations seriously overestimated the numbers of PCIs the
linear method was not further considered. Model 5, which
also incorporates modifications to risk of a PCI and risk of
a CABG has considerably better forecasts. There is now
only 6.1 percent over-estimation of number of CABGs
under Model 5 while for PCIs there is an under-estimation
by only 3 percent.
a. Plot for risk of a CABG within a year, for people with no history of CHD by calendar year, for males with different age groupsFig re 4
a. Plot for risk of a CABG within a year, for people with no history of CHD by calendar year, for males with different age 
groups. b. Plot for risk of a CABG within a year, for people with no history of CHD by calendar year, for females with different 
age groups
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In this paper we have examined forecasts for 1995–1999
based on extrapolation of trends from 1992–94. This was
done because actual event numbers were known for these
years and to illustrate the need to modify the standard
methods in a period like this when there were rapid
changes in CARP surgical technology and practice. How-
ever, the limitations of the retrospective nature of this
study should be acknowledged. We believe that the mod-
ifications could have been anticipated in 1995 when
knowledge of increased PCI effectiveness was becoming
available and the changing preference for PCI over CABG
was common knowledge among cardiologists and cardio-
thoracic surgeons. However, quantifying the impacts of
these expected changes in 1995 would have been more
difficult than in our illustration which used evidence pub-
lished after 1995.
a. Plot for risk of a PCI, for people with no history of CHD by calendar year, for males with different age groupsFigure 5
a. Plot for risk of a PCI, for people with no history of CHD by calendar year, for males with different age groups. b. Plot for 
risk of a PCI, for people with no history of CHD by calendar year, for females with different age groups
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effects of risk factors such as blood pressure, cholesterol,
obesity and smoking on event risks. Whilst cohort-based
models that incorporate risk factors have been proposed
(eg, Sesso et al. [17]) it is not practical to incorporate risk
factors directly into our model because it has 96 different
risks (for each age and sex group) and thus 96 risk factor
models would be required. Further, as our model simu-
lates individual pathways, such an approach would also
require risk factor data on the entire population of West-
ern Australia. However, our model can still indirectly
incorporate changes in trends in risk factors by appropri-
ate modification of model probabilities that relate to risk
of certain CHD events (eg for people currently with no
history of CHD).
Using the approach of modifying selected and relevant
model event probabilities, our model is flexible enough to
explore the effect on the future requirements of CARPs of
a variety of changing circumstances. In addition to
advances in surgical procedures and changing preference
for surgical procedures as we have illustrated, other sce-
narios such as changes in the effectiveness of, and access
to, medical treatments may be investigated. For example,
randomized controlled trials have shown that there were
significant reductions in requirements for CARPs among
higher risk individuals who were given antiplatelet ther-
apy versus controls [18]. An example of a possible change
in health policy related to treating CHD patients could be
the availability of low cost statins [19]. Since the cost of
the Australian Pharmaceutical Benefit Scheme which sub-
sidizes the cost of statin drugs has been increasing rapidly,
the government may change its current policy and only
provide subsidy to people at higher risk of CHD. The
effect of these changes relating to medical treatments
could be investigated using our CHD/CARP model
through modifications to selected and relevant model
probabilities.
The CHD/CARP model can also be extended and used to
determine the cost of future requirements for CARPs and
to explore the most cost-effective strategies for treatment
of CHD. To achieve this, indicative cost estimates are
needed for each of the alternative CARP treatments for
each year. For more description of cost effectiveness anal-
ysis one can refer to some studies which have evaluated
economic impact of drug-eluting stents [20,21], and cost
effectiveness of CHD prevention through CHD risk reduc-
tion strategies [22].
Conclusion
It is clear from the model simulation results that forecast-
ing events in an era of rapid changes is fraught with diffi-
culties and standard extrapolation methods are not likely
to perform well in such situations. However, there is often
knowledge and sometimes quantitative evidence of the
expected impacts of changes in procedure effectiveness
and practice and these may be used to modify the stand-
ard forecasting methods to achieve better forecasts as we
have illustrated. The simulation results implied that mod-
ifications that related to the changing relative use of a PCI
to a CABG were more important for correctly projecting
the numbers of CARPs than modifications that related
only to the increased effectiveness of PCI procedures.
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